Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

BACKGROUND: Patient-reported outcomes (PROs) are increasingly becoming an important part of clinical trials as they are helpful in analyzing the safety and efficacy of treatment in chronic diseases like cancer. OBJECTIVES: We report PROs and health-related quality of life (HRQoL) with selpercatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Zheng, Xiangqian, Sun, Yuping, Huang, Dingzhi, Wu, Lin, Ji, Qinghai, Zhou, Chengzhi, Zhou, Jianying, Guo, Ye, Ge, Minghua, Ding, Ding, Shao, Jingxin, Zhang, Wanli, Gao, Ming, Cheng, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467255/
https://www.ncbi.nlm.nih.gov/pubmed/37655205
http://dx.doi.org/10.1177/17588359231189429

Ejemplares similares

Ejemplares similares